Joaquín Arribas

Vall d'Hebron Institut d'Oncologia

Life & Medical Sciences

Joaquín Arribas completed his undergraduate studies in biochemistry at the Universidad Autónoma de Madrid in 1987. At the same university he subsequently worked on the regulation of the catalytic activities of the proteasome and received his PhD in Biology in 1991. Sponsored by a fellowship from the Spanish Ministry of Education and Science, he joined the Memorial Sloan-Kettering Cancer Center, New York (USA), as a Postdoctoral Fellow to work with J. Massagué (1992-1996) on the proteolytic processing of transmembrane growth factors. In 1997 he joined the oncology department at Hospital Vall d'Hebron in Barcelona as a Staff Scientist, since then he has lead the research group on Growth Factors. Since 2010 he has served as Director of VHIO´s Preclinical Research Program. His research has been recognized through an EMBO Young Investigator Programme (YIP) Award and the Beckman Coulter Award for the Best Young Spanish Investigator in Biochemistry and Molecular Biology.

Research interests

* Determine the therapeutic value of the anti-p95HER2 antibodies to treat breast cancers.

* Analyze cellular heterogeneity of HER2-positive breast tumors.

* Explore the link between HER2-driven senescence and breast cancer invasion.

Selected publications

- Pedersen K, Bilal F, Bernadó Morales C, Salcedo MT, Macarulla T, Massó-Vallés D, Mohan V, Vivancos A, Carreras M, Serres X, Abu-Suboh M, Balsells J, Allende E, Sagi I, Soucek L, Tabernero J & Arribas J 2017, 'Pancreatic cancer heterogeneity and response to Mek inhibition', Oncogene, 36, 40, 5639 - 5647.

- Rios-Luci C, Garcia-Alonso S, Diaz-Rodriguez E, Nadal-Serrano M, Arribas J, Ocana A & Pandiella A 2017, 'Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity', Cancer Research, 77, 17, 4639 - 4651.

- Sabbaghi MA, Gil-Gomez G, Guardia C, Servitja S, Arpi O, Garcia-Alonso S, Menendez S, Arumi-Uria M, Serrano L, Salido M, Muntasell A, Martinez-Garcia M, Zazo S, Chamizo C, Gonzalez-Alonso P, Madoz-Gurpide J, Eroles P, Arribas J, Tusquets I, Lluch A, Pandiella A, Rojo F, Rovira A & Albanell J 2017, 'Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer', Clinical Cancer Research, 23, 22, 7006 - 7019.

- Byrne AT et al. 2017, 'Interrogating open issues in cancer medicine with patient-derived xenografts', Nature Reviews Cancer, 17, 10.

- Martin-Perez R, Yerbes R, Mora-Molina R, Cano-Gonzalez A, Arribas J, Mazzone M, Lopez-Rivas A & Palacios C 2017, 'Oncogenic p95HER2/611CTF primes human breast epithelial cells for metabolic stress-induced down-regulation of FLIP and activation of TRAIL-R/Caspase-8-dependent apoptosis', Oncotarget, 8, 55, 93688 - 93703.